Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis

    • Coronavirus disease (COVID-19)

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Scientific Resources
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

Attacking Cancer Cells That Develop Resistance

Attacking Cancer Cells That Develop Resistance
OUR SCIENCE/ Attacking Cancer Cells That Develop Resistance
January 23, 2020

By Get Science Staff - This article originally published on Get Science

When cancer patients receive therapy for an extended time, they often face the specter of drug resistance as tumor cells mutate and find ways to evade the cancer-killing medicines.

Exploring new ways to disarm rogue cells that have developed resistance is a major field of modern cancer research. One way to address the issue of resistance is to attack cancer through the fundamental processes that drive their core mission — to multiply unchecked and invade healthy organs.

Unlike traditional chemotherapy, which essentially poisons the cancer cells, medicines called cell-cycle kinase inhibitors put the brakes on uncontrolled cancer cell proliferation by blocking only key enzymes that drive cell division. 

Researchers have discovered that a class of kinase enzymes, the cyclin-dependent kinases, or CDKs, are commonly over-active in hormone receptor-positive breast cancer. Specific inhibition of certain CDKs in combination with anti-hormonal therapy is beneficial to this patient population, explains Dr. Stephen Dann, Senior Principal Scientist at Pfizer’s R&D site in La Jolla, California. “It's a very novel mechanism because instead of just shutting down a cancer gene, which is the mechanism used by a lot of targeted therapies, this kinase inhibitor actually reactivates a tumor suppressor.”

cyclin-dependent_kinase_inhibitor_complex.775x716_1.jpg

And using kinase inhibitors to mount a frontal assault on the machinery that drives cancer cell proliferation isn’t the end of the story. “While Pfizer does have an approved CDK inhibitor, cancers activate a different kinase to start growing again,” Dr. Dann says. When researchers discovered this was the case, they started working on strategies to address likely resistance.  

“Tumor cells are always trying to find loopholes,” he says. “So, my work is focused on determining those mechanisms of resistance. We’re trying to figure out ways that the disease gets around that kinase inhibitor,” Dr. Dann says. “It's like having a half-filled balloon—you squeeze on one side and it just pops out the other. That's what's happening in a tumor cell. You're getting a lot of very quick evolution where those cells that survive tend to be more and more aggressive.”

“When you're targeting a cancer gene, it's often a game of whack-a-mole, where you hit the cancer cell adaptation as it comes up,” Dr. Dann adds.

Recent research by Dr. Dann and his team in breast cancer has zeroed in on next-gen medicines that specifically target additional CDK enzymes. For reasons that are still being uncovered, these inhibitors show promise in addressing resistance to certain CDK inhibitors. 

Targeting those specific types of CDK enzyme is like trying to “thread the needle,” he says, in that you’re trying to reactivate that tumor suppressor while at the same time suppressing the CDK enzymes to just the right degree to avoid toxic side-effects to healthy cells. “We’re hopeful that cancer cell adaptation to this class of compound is going to be difficult to achieve in patients.”

Early clinical trials for this new generation of kinase inhibitors are underway and could yield invaluable insights into approaches to control malignant disease and combat the issue of resistance.

Related Hot Topics
An Early Passion for Science and Public Health Inspires Adriana’s Work
An Early Passion for Science and Public Health Inspires Adriana’s Work
Sandy Focuses on Diversity in Our Clinical Trials
Sandy Focuses on Diversity in Our Clinical Trials
“The Ice Man” - The Pfizer Colleague & Dad Who Keeps Our Medicines and Vaccines on Ice
“The Ice Man” - The Pfizer Colleague & Dad Who Keeps Our Medicines and…
New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent Scientific Research is Moving Forward Patient Care
New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent…
Other Diseases
Deserve the Same Acceleration as
COVID-19: A BioCentury Audio Interview with Rod MacKenzie
Other Diseases Deserve the Same Acceleration as COVID-19
Moving at the Speed of Science
Moving at the Speed of Science
Improving Care and Support for People Living with Breast Cancer
Improving Care and Support for People Living with Breast Cancer
Woman-Made: Hear from Women at Pfizer With Careers in Modern Manufacturing
Woman-Made: Hear from Women at Pfizer With Careers in Modern Manufacturing
Tags
Breast cancer
Get Science
science
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.